Psilocybin opioid study pulled before it began
NCT ID NCT06005662
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to see if adding a single high dose of psilocybin (30 mg) to standard buprenorphine treatment could help people with opioid use disorder stay off illicit opioids and improve their quality of life. It planned to enroll adults aged 21–70 who were not already on opioid medications. However, the study was withdrawn before enrolling any participants, so no results are available.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OPIOID-USE DISORDER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Johns Hopkins University
Baltimore, Maryland, 21224, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new tool better measure opioid withdrawal?
- Giving patients a voice in methadone care: a new approach under the microscope
- Can a sleep pill boost success in opioid treatment?
- Can coaching clinics curb HIV? a new strategy puts it to the test
- Could a trip to the pediatrician help teens beat opioid addiction?
- A nose spray before treatment: could naloxone speed up opioid recovery for fentanyl users?